T cell exhaustion is not simply a temporary state of immune fatigue. It represents a complex and relatively stable cellular reprogramming process involving inhibitory receptors, epigenetic remodeling, altered transcription-factor networks, and metabolic dysfunction. When T cells repeatedly encounter antigens from a transplanted organ, they can enter a progressive pathway that begins with functional changes and may culminate in terminal exhaustion. During this process, their capacity for proliferation and effector activity declines, while molecular programs that limit excessive tissue damage become increasingly dominant.

Four immune checkpoint receptors are especially important in this transition: PD-1, CTLA-4, TIM-3, and LAG-3. These molecules transmit inhibitory signals that reduce T cell activation through partly distinct but overlapping pathways. PD-1, for example, can suppress signaling downstream of the T cell receptor by recruiting phosphatases that interfere with activation pathways. CTLA-4 competes with the stimulatory receptor CD28 for binding to costimulatory molecules on antigen-presenting cells. TIM-3 and LAG-3 add further layers of inhibition. Their sustained expression helps maintain exhaustion and can prevent alloreactive T cells from causing extensive damage to transplanted tissue.

The review emphasizes that the exhausted state is reinforced by epigenetic changes that alter how genes are accessed and expressed. DNA methylation, histone modifications, and large-scale chromatin remodeling establish a regulatory landscape distinct from that of effector or memory T cells. These changes can remain after the original antigenic stimulus has been reduced or removed, producing an enduring molecular imprint sometimes described as “epigenetic scarring.” This persistence helps explain why exhausted T cells may not fully recover even when immune conditions change, and why simply blocking inhibitory receptors may not restore their original function.

A network of transcription factors directs the development of exhaustion. TOX is presented as a central regulator, promoting inhibitory receptor expression and activating genes associated with the exhausted phenotype while suppressing programs linked to powerful effector responses. NFAT, NR4A, BATF, IRF4, MYB, and TCF-1 also contribute to the process. TCF-1 is particularly associated with progenitor exhausted cells, a self-renewing population capable of producing more differentiated exhausted cells. This hierarchical organization suggests that exhaustion is not uniform: some exhausted T cells retain proliferative potential and may respond to therapeutic intervention, whereas terminally exhausted cells are more deeply locked into dysfunctional states.

Metabolism provides another critical explanation for declining T cell performance. Activated effector T cells normally increase glucose uptake and rely heavily on glycolysis to generate energy and biosynthetic materials rapidly. Exhausted T cells show impaired glucose utilization and reduced glycolytic capacity. They may become more dependent on fatty acid oxidation, while also developing mitochondrial abnormalities, reduced ATP production, and disturbed amino acid metabolism. Mitochondria can become less efficient and accumulate stress, limiting the energy available for cytokine production and cell division. These metabolic changes are not merely consequences of exhaustion; they can actively reinforce the transcriptional and epigenetic programs that sustain it.

In transplantation, a controlled degree of exhaustion may be beneficial. By reducing the activity of T cells that recognize donor antigens, exhaustion can diminish alloreactive responses, lower the risk of rejection, and contribute to graft acceptance. The effect appears to vary according to the transplanted organ. In kidney transplantation, increased populations of exhausted T cells have been linked in some studies with improved graft function and features of immune tolerance. The liver, naturally exposed to a continuous flow of dietary and microbial antigens, possesses an especially tolerogenic environment that can favor exhaustion. In hematopoietic stem cell transplantation, exhausted donor T cells may reduce graft-versus-host disease, although the same process can weaken graft-versus-leukemia activity, which is essential for eliminating malignant cells.

The immune environment surrounding a graft can actively drive this process. Regulatory T cells, myeloid-derived suppressor cells, M2-polarized macrophages, and natural killer cells may interact with T cells in ways that suppress activation and promote exhaustion. Soluble mediators are also important. TGF-β can reshape transcriptional and epigenetic programs, while IL-10 dampens inflammatory signaling and alters cellular metabolism. Together, these factors can create a local suppressive niche in which exhausted T cells are maintained. Yet excessive suppression carries a cost: antiviral surveillance may decline, allowing latent or newly acquired infections to become more difficult to control, while impaired immune monitoring may increase the risk of post-transplant malignancies.

The authors argue that future transplantation therapies should aim not simply to eliminate exhaustion, but to manage it with greater precision. Strategies could include manipulating checkpoint pathways, modifying metabolic conditions, targeting exhaustion-associated transcription factors, or reshaping the epigenetic state of T cells. The greatest challenge will be separating protective exhaustion, which limits graft injury, from harmful exhaustion, which compromises infection control and tumor surveillance. A better understanding of progenitor and terminally exhausted populations could eventually allow clinicians to preserve tolerance while restoring selected immune functions. The review therefore presents T cell exhaustion as a dynamic therapeutic target—one that may be deliberately induced, restrained, or reversed depending on the clinical needs of each transplant recipient.

Subject of Research: T cell exhaustion in organ transplantation and its molecular mechanisms, clinical effects, and therapeutic modulation.

Article Title: The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies

Web References: https://doi.org/10.1016/j.gendis.2025.101965

References: Yining Wang, You Wu, Yufei Shen, Yujia Chen, Yifan Zhao, Xiandong Zeng, Kang He. “The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies.” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101965.

Image Credits: Genes & Diseases

Keywords: T cell exhaustion, organ transplantation, immune tolerance, graft rejection, PD-1, CTLA-4, TIM-3, LAG-3, epigenetics, TOX, TCF-1, metabolism, transplant immunology

Tacrolimus, a cornerstone immunosuppressant used to prevent organ rejection, presents a narrow therapeutic index, with significant variability in pharmacokinetics and pharmacodynamics among individuals. This variability often necessitates meticulous and frequent dose adjustments to mitigate risks such as graft rejection or drug toxicity. Traditional dosing protocols rely heavily on population-based averages, which may inadequately account for patient-specific factors influencing drug metabolism and response.

The study spearheaded by Khong, Lee, Warren, and collaborators addresses this critical gap by employing phenotypic markers to tailor tacrolimus dosing. Phenotypic personalized medicine here refers to assessing measurable biological characteristics—such as enzyme activity levels, drug metabolite profiles, and immunological parameters—that offer real-time insight into an individual patient’s drug disposition and immune status. Incorporating these phenotypes facilitates a more precise dosing strategy that transcends the current “one-size-fits-most” paradigm.

In this rigorous randomized controlled trial, liver transplant recipients were assigned to either standard dosing protocols or a phenotypic-guided dosing arm. The phenotypic approach integrated biomarker assessments, including cytochrome P450 3A5 (CYP3A5) enzyme genotyping and metabolic activity assays, alongside immune function assays, to dynamically modulate tacrolimus doses. This methodology harnesses advances in molecular diagnostics and immunology to personalize therapy in a clinically meaningful manner.

One of the pivotal findings of this phase 2 trial was the enhanced stability of tacrolimus blood concentrations among patients receiving phenotypic-guided dosing. This stability is clinically significant because it reduces the incidence of subtherapeutic exposure that predisposes patients to rejection episodes as well as supratherapeutic levels that contribute to nephrotoxicity and other adverse events. The phenotypic approach demonstrated a notable reduction in dose adjustments and outpatient visits for therapeutic drug monitoring, underscoring its potential to improve healthcare efficiency.

Moreover, the trial revealed that phenotypic dosing correlated with a lower incidence of acute rejection during the critical early post-transplant period, hinting at improved immunological control through optimized drug exposure. This is remarkable given how early graft rejection substantially affects long-term transplant success and patient survival. By finely tuning immunosuppression, phenotypic-guided protocols may strike a better immunological balance, preserving graft function without overtreatment.

This study’s strength lies in its multidisciplinary integration of pharmacogenomics, pharmacokinetics, and immunophenotyping, highlighting the convergence of these fields to tailor therapy on an individual basis. Importantly, the researchers utilized advanced bioanalytical techniques to capture dynamic phenotypic data, which required sophisticated laboratory infrastructure and clinical expertise. These developments mark a significant step toward precision medicine in transplantation, a field that has long lagged behind oncology and other areas in personalized approaches.

The implications extend beyond liver transplantation. Tacrolimus remains a mainstay for kidney, heart, and lung transplants, where similar pharmacologic challenges persist. If phenotypic personalized dosing proves robust across organ types and larger cohorts, it could herald a new era of immunosuppressive management, potentially decreasing morbidity, improving graft longevity, and reducing healthcare costs.

The study also underscores the evolving role of machine learning and computational modeling in transplant pharmacology. The integration of phenotypic data can feed into predictive algorithms that anticipate an individual’s response to tacrolimus, adapting doses preemptively rather than reactively. This proactive dosing paradigm could revolutionize clinical workflows, transforming tacrolimus management into a dynamic, data-informed practice rather than a static protocol-driven one.

However, certain challenges remain before widespread clinical adoption. The need for specialized assays and the cost of phenotyping may limit immediate accessibility, particularly in resource-constrained settings. Additionally, the complexity of transplant immunology means phenotypic personalization may never be fully predictive; hence, clinical judgment remains indispensable. Long-term studies are necessary to validate the durability of benefits concerning graft survival and patient quality of life.

Furthermore, this trial paves the way for exploring additional biomarkers that could refine immunosuppressive regimens. Beyond CYP3A5 and metabolite monitoring, inflammatory cytokines, immune cell subset profiling, and even microbiome interactions might emerge as influential factors governing tacrolimus response. Such multidimensional phenotyping could further enhance individualized therapy, aligning with the larger precision medicine movement sweeping through healthcare.

Another fascinating aspect is the psychosocial and patient engagement angle. Personalized dosing strategies inherently require close communication between patients and clinicians, fostering collaborative care models. Patients empowered with knowledge about their unique drug response characteristics may exhibit improved adherence and satisfaction, factors which are crucial for the success of long-term therapies vital in transplantation.

This investigation into phenotypic dosing also challenges the regulatory and logistical frameworks governing transplant pharmacotherapy. Integrating innovative diagnostic tools into clinical practice demands updates to guidelines, reimbursement policies, and practitioner education. Stakeholders including transplant centers, laboratories, and policymakers must collaborate to create environments conducive to adopting personalized immunosuppression strategies.

In summary, Khong and colleagues’ landmark phase 2 clinical trial introduces a compelling vision for tacrolimus dosing in liver transplant recipients by harnessing phenotypic personalized medicine. Their work elucidates the potential for improved drug exposure stability, reduced rejection risk, and enhanced patient care through individualized therapeutic regimens grounded in deep biological insight. This approach embodies the future of transplantation, where precision and personalization are not aspirational but integral components of clinical practice, offering hope for enhanced transplant success in the years ahead.

Subject of Research: Tacrolimus dosing optimization in liver transplant recipients using phenotypic personalized medicine.

Article Title: Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial.

Article References:
Khong, J., Lee, M., Warren, C. et al. Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial. Nat Commun 16, 4558 (2025). https://doi.org/10.1038/s41467-025-59739-6

Image Credits: AI Generated